Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?

BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...
PharmiWeb

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...
Cantech Letter

Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications

The subcutaneous administration of the established immunotherapy could free up an estimated 30,000 hours of infusion chair ...
Managed Healthcare Executive

Modified dosing of melanoma immunotherapy shows better results, fewer side effects

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...